JP2021532784A5 - - Google Patents

Info

Publication number
JP2021532784A5
JP2021532784A5 JP2021505393A JP2021505393A JP2021532784A5 JP 2021532784 A5 JP2021532784 A5 JP 2021532784A5 JP 2021505393 A JP2021505393 A JP 2021505393A JP 2021505393 A JP2021505393 A JP 2021505393A JP 2021532784 A5 JP2021532784 A5 JP 2021532784A5
Authority
JP
Japan
Prior art keywords
seq
peptide
pharmaceutically acceptable
acceptable salt
oligonucleotide complex
Prior art date
Application number
JP2021505393A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532784A (ja
JPWO2020028254A5 (https=
JP7564087B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/043920 external-priority patent/WO2020028254A1/en
Publication of JP2021532784A publication Critical patent/JP2021532784A/ja
Publication of JP2021532784A5 publication Critical patent/JP2021532784A5/ja
Publication of JPWO2020028254A5 publication Critical patent/JPWO2020028254A5/ja
Application granted granted Critical
Publication of JP7564087B2 publication Critical patent/JP7564087B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021505393A 2018-07-30 2019-07-29 アンチセンス送達のための三量体ペプチド Active JP7564087B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862711894P 2018-07-30 2018-07-30
US62/711,894 2018-07-30
PCT/US2019/043920 WO2020028254A1 (en) 2018-07-30 2019-07-29 Trimeric peptides for antisense delivery

Publications (4)

Publication Number Publication Date
JP2021532784A JP2021532784A (ja) 2021-12-02
JP2021532784A5 true JP2021532784A5 (https=) 2022-07-29
JPWO2020028254A5 JPWO2020028254A5 (https=) 2022-07-29
JP7564087B2 JP7564087B2 (ja) 2024-10-08

Family

ID=69230560

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021505393A Active JP7564087B2 (ja) 2018-07-30 2019-07-29 アンチセンス送達のための三量体ペプチド

Country Status (5)

Country Link
US (2) US12168059B2 (https=)
EP (1) EP3829597A4 (https=)
JP (1) JP7564087B2 (https=)
TW (1) TW202019442A (https=)
WO (1) WO2020028254A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52148A (fr) * 2018-03-16 2021-01-20 Sarepta Therapeutics Inc Peptides chimères pour administration d'antisens
EP3790890A4 (en) 2018-05-09 2022-03-02 Ohio State Innovation Foundation CYCLIC, CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RAILS
WO2021150867A1 (en) * 2020-01-24 2021-07-29 Sarepta Therapeutics, Inc. Designing antisense oligonucleotide delivery peptides by interpretable machine learning
WO2022240721A1 (en) * 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
WO2022240760A2 (en) * 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING
US20240358845A1 (en) * 2021-05-10 2024-10-31 Entrada Therapeutics, Inc. Compositions and methods for intracellular therapeutics
AU2022313315A1 (en) * 2021-07-23 2024-02-08 Beam Therapeutics Inc. Guide rnas for crispr/cas editing systems
WO2023191953A1 (en) 2022-03-26 2023-10-05 University Of Rhode Island Board Of Trustees Pnictogen-containing heterocyclic compounds and their use
WO2023192510A1 (en) * 2022-03-31 2023-10-05 Entrada Therapeutics, Inc. β-CATENIN ANTIBODIES
WO2026080471A2 (en) 2024-10-07 2026-04-16 Flagship Pioneering Innovations Vi, Llc Compositions of trem conjugates and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161948B2 (en) * 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2012150960A1 (en) 2011-05-05 2012-11-08 Avi Biopharma, Inc. Peptide oligonucleotide conjugates
WO2015069665A1 (en) * 2013-11-06 2015-05-14 Rain Bioscience, Inc. Intracellular delivery system for oligomers having low renal clearance rate
EP3297649B1 (en) * 2015-05-19 2023-10-11 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates

Similar Documents

Publication Publication Date Title
JP2021532784A5 (https=)
JP2758988B2 (ja) ペプチド核酸
US10793605B2 (en) Conformationally-preorganized, miniPEG-containing γ-peptide nucleic acids
CN101547932B (zh) 核苷芳基氨基磷酸酯及其作为抗病毒制剂处理丙型肝炎病毒的应用
FI120261B (fi) PNA-synteesi käyttämällä heikkojen happojen suhteen labiilia aminonsuojaryhmää
JP2018530560A5 (https=)
JP2020537654A5 (https=)
NZ243000A (en) Tachykinin derivative
JPWO2020028254A5 (https=)
US6713602B1 (en) Synthetic procedures for peptide nucleic acids
De Cola et al. Carboxyalkyl peptoid PNAs: synthesis and hybridization properties
ITMI951450A1 (it) Esteri acilici di amminoacidi achirali di gangiclovir e relativi derivati
AU2024265463A1 (en) Preparation of peptide inhibitor of interleukin-23 receptor and use thereof
SK2793A3 (en) Polypeptide compounds with ability release of growth hormone
JP2021515005A5 (https=)
HUE028918T2 (en) Effective peptide couplings and their use in the synthesis and isolation of cyclopenta (G) quinazoline trinodium salt
JP2025513521A5 (https=)
JPWO2023127752A5 (https=)
AU2022291626A1 (en) Improved process for preparing imetelstat
JPWO2019178479A5 (https=)
JP2020537652A5 (https=)
US7038037B2 (en) Method for sequential support-bound synthesis of conjugated oligomeric compounds
US9017673B2 (en) Peptide analogues comprising at least one type of aminoacylaza-$g(b)<sp>3</sp>and the use thereof, in particular for therapy
KR20230109301A (ko) 신규한 pna 단량체 및 이를 포함하는 pna 올리고머
Ferrer et al. Synthesis of peptide nucleic acid oligomers carrying 5-methylcytosine derivatives by postsynthetic substitution